Broxuridine

Modify Date: 2026-07-01 08:06:45

Broxuridine Structure
Broxuridine structure
 Common Name Broxuridine
CAS Number 59-14-3 Molecular Weight 307.098
Density 1.9±0.1 g/cm3 Boiling Point N/A
Molecular Formula C9H11BrN2O5 Melting Point 191-194 °C (dec.)(lit.)
MSDS Chinese USA Flash Point N/A
Symbol GHS08
GHS08		 Signal Word Danger

 Use of Broxuridine


5-BrdU is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.

Summary: 5-Bromo-2'-deoxyuridine, also known as Broxuridine, has a CAS number of 59-14-3, with a molecular formula of C9H11BrN2O5 and a molecular weight of 307.098. It appears as a white crystalline powder with a melting point of 191-194 °C (dec.) and a density of 1.9±0.1 g/cm3.主要用于脑瘤和头颈部肿瘤的放射增敏剂，也可用作诱变剂，在细胞分裂S-期选择性地插进DNA. For research-use only, not for medical or clinical usage.

 Names

This table lists Chinese names, IUPAC names and various aliases of this chemical substance.

Name 5-bromo-2'-deoxyuridine
Synonym More Synonyms

 Broxuridine Biological Activity

This table contains bioactivity, target information and biological‑assay experimental data of this compound.

Description 5-BrdU is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.
Related Catalog
In Vitro Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion RG2 rat glioma cells. In H9 cells and BJ fibroblasts, bromodeoxyuridine alters the cell cycle profile[1]. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession[2]. 
In Vivo Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/mL, p.o.) significantly slows tumor progression in rat glioma RG2 tumor model[1].
Cell Assay Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 µM BrdU for 24 hours, and cumulative growth curves are obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.
References

[1]. Levkoff LH, et al. Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo. Neoplasia. 2008 Aug;10(8):804-16.

[2]. Rothaeusler K, et al. Assessment of cell proliferation by 5-bromodeoxyuridine (BrdU) labeling for multicolor flow cytometry. Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31

 Chemical & Physical Properties

This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.

Density 1.9±0.1 g/cm3
Melting Point 191-194 °C (dec.)(lit.)
Molecular Formula C9H11BrN2O5
Molecular Weight 307.098
Exact Mass 305.985138
PSA 104.55000
LogP -0.81
Index of Refraction 1.652
InChIKey WOVKYSAHUYNSMH-RRKCRQDMSA-N
SMILES O=c1[nH]c(=O)n(C2CC(O)C(CO)O2)cc1Br
Water Solubility 1-5 g/100 mL at 22 ºC

 MSDS

This table provides MSDS information including hazard classification, first‑aid, fire‑fighting, spill handling, operation and storage instructions.

 Toxicological Information

This table summarizes toxicological test data, acute & chronic toxicity and ecological hazard parameters for this chemical.

CHEMICAL IDENTIFICATION

RTECS NUMBER :
YU7350000
CHEMICAL NAME :
Uridine, 5-bromo-2'-deoxy-
CAS REGISTRY NUMBER :
59-14-3
BEILSTEIN REFERENCE NO. :
0030395
LAST UPDATED :
199712
DATA ITEMS CITED :
151
MOLECULAR FORMULA :
C9-H11-Br-N2-O5
MOLECULAR WEIGHT :
307.13
WISWESSER LINE NOTATION :
T6NVMVJ EE A- ET5OTJ B1Q CQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3900 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2320 mg/kg
TOXIC EFFECTS :
Vascular - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2300 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9100 mg/kg
TOXIC EFFECTS :
Behavioral - muscle weakness Blood - changes in spleen Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3050 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2500 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Cardiac - pulse rate Lungs, Thorax, or Respiration - respiratory depression
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - quail
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
16 mg/kg
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Endocrine - thyroid tumors Reproductive - Tumorigenic effects - testicular tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
250 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
700 mg/kg
SEX/DURATION :
female 9-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
600 mg/kg
SEX/DURATION :
female 8-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
300 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
200 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
40 mg/kg
SEX/DURATION :
female 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
300 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1200 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
600 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 gm/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
1 gm/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
500 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
640 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
900 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
400 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Mutation in mammalian somatic cells
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Heritable translocation test
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sister chromatid exchange

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange
TEST SYSTEM :
Mammal - species unspecified Fibroblast
DOSE/DURATION :
100 umol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 254,13,1991 *** REVIEWS *** TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4811 No. of Facilities: 3 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 6 (estimated) No. of Female Employees: 3 (estimated)

 Safety Information

This table covers safety warnings, protective measures, incompatible substances and disposal guidelines for this compound.

Symbol GHS08
GHS08
Signal Word Danger
Hazard Statements H340-H361
Precautionary Statements P201-P281-P308 + P313
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xn:Harmful;
Risk Phrases R36/37/38;R68
Safety Phrases S36/37/39-S26
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS YU7350000

 Synthetic Route

This table presents publicly reported synthetic routes, reaction conditions, reactants and product information of the compound.

 Articles273

More Articles

This table lists relevant public references with title, journal and publication metadata for this compound.

Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current.

Oncotarget 5(22) , 11252-68, (2014)

Epidemiological and preclinical studies propose that metformin, a first-line drug for type-2 diabetes, exerts direct antitumor activity. Although several clinical trials are ongoing, the molecular mec...

Transplantation of enteric neural stem/progenitor cells into the irradiated young mouse hippocampus.

Cell. Transplant. 23(12) , 1657-71, (2015)

Radiotherapy is an effective treatment for brain tumors but often results in cognitive deficits in survivors. Transplantation of embryonic or brain-derived neural stem/progenitor cells (BNSPCs) amelio...

FGFR1 mediates recombinant thrombomodulin domain-induced angiogenesis.

Cardiovasc. Res. 105(1) , 107-17, (2014)

The recombinant epidermal growth factor-like domain plus the serine/threonine-rich domain of thrombomodulin (rTMD23) promotes angiogenesis and accelerates the generation of activated protein C (APC), ...

 Synonyms

This table collects all English aliases, systematic names and CAS‑related synonyms of the compound.

5-Br-2'-Udr
5-Bromo-2'-deoxyuridine
EINECS 200-415-9
5-Bromo-2`-deoxyuridine
5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
Bromouracil deoxyriboside
MFCD00006529
5-Bromo-2′-deoxyuridine
Bromodeoxyuridine
Radibud
5-Bromo-1-(2-deoxy-Beta-D-ribofuranosyl)uracil5-Bromouracil deoxyriboside
UNII-G34N38R2N1
5-Bromouracil deoxyriboside
5-BrdU
Broxuridine
5-BrdU,5-Bromo-1-(2-deoxy-Beta-D-ribofuranosyl)uracil5-Bromouracil deoxyriboside,BUdR
(+)-5-BROMO-2'-DEOXYURIDINE
5-Bromodeoxyuridine
BRDU
5-Bromodesoxyuridine
BUDR

 Broxuridine | FAQ

This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.

Q: What is the InChIKey of 5-bromo-2'-deoxyuridine?
A: InChIKey of 5-bromo-2'-deoxyuridine is WOVKYSAHUYNSMH-RRKCRQDMSA-N.
Q: What are the downstream products of 5-bromo-2'-deoxyuridine?
A: Related downstream products(CAS) of 5-bromo-2'-deoxyuridine: 6161-23-5;50-89-5;951-78-0;154925-95-8;40733-26-4.
Q: What are the upstream materials of 5-bromo-2'-deoxyuridine?
A: Related upstream materials(CAS) of 5-bromo-2'-deoxyuridine: 951-78-0;51-20-7;6161-23-5;54-42-2;1463-10-1;951-77-9;50-89-5;13030-62-1;146629-34-7.
Q: What is the safety information for 5-bromo-2'-deoxyuridine?
A: Safety information for 5-bromo-2'-deoxyuridine: S36/37/39-S26.
Q: What is the LogP of 5-bromo-2'-deoxyuridine?
A: LogP of 5-bromo-2'-deoxyuridine is -0.81.
Q: What is the CAS number of 5-bromo-2'-deoxyuridine?
A: CAS number of 5-bromo-2'-deoxyuridine is 59-14-3.
Q: What is the melting point of 5-bromo-2'-deoxyuridine?
A: Melting point of 5-bromo-2'-deoxyuridine is 191-194 °C (dec.)(lit.).
Q: What is the molecular formula of 5-bromo-2'-deoxyuridine?
A: Molecular formula of 5-bromo-2'-deoxyuridine is C9H11BrN2O5.
Q: How is the water solubility of 5-bromo-2'-deoxyuridine?
A: Water solubility of 5-bromo-2'-deoxyuridine: 1-5 g/100 mL at 22 ºC.
Q: What is the molecular weight of 5-bromo-2'-deoxyuridine?
A: Molecular weight of 5-bromo-2'-deoxyuridine is 307.098.

 Broxuridinefactory

This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.

Shanghai Nianxing Industrial Co., Ltd
Dayang Chem (Hangzhou) Co., Ltd.
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Broxuridine suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Broxuridine price

Related Compounds: More...
1h-Pyrrolo[2,3-c]pyridine-5-carboxylic acid,1-[(2,4-difluorophenyl)methyl]-3-[[4-hydroxy-4-[(2-oxo-1-pyrrolidinyl)methyl]-1-piperidinyl]methyl]
879399-26-5
3-Hydroxy-4-[2-(oxolan-2-yl)acetamido]benzoic acid
1478726-73-6
2-Bromo-5-fluoro-6-iodoanisole
2179038-32-3
5-(1-Cyano-1-methylethyl)-2-furoic acid
878742-44-0
2-Phenyl-1-((trifluoromethyl)sulfonyl)-1H-imidazole
955997-83-8
5-(1H-1,2,3-triazol-1-yl)pentanoic acid
1453111-79-9
5-(1H-1,2,3-Triazol-4-yl)pentanoic acid
1461714-38-4
2-[(6-Bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino]benzonitrile
1309593-61-0
5-chloro-1,3-dimethyl-1H-pyrazole-4-thiol
2229599-27-1
N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-2-ethoxybenzamide
1222509-93-4
Chemsrc provides Broxuridine(CAS#:59-14-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Broxuridine are included as well.>> amp version: Broxuridine

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved